Contineum Therapeutics, Inc.’s Quiet Period Set To End on May 15th (NASDAQ:CTNM)

Contineum Therapeutics’ (NASDAQ:CTNM) quiet period will expire on Wednesday, May 15th. Contineum Therapeutics had issued 6,875,000 shares in its initial public offering on April 5th. The total size of the offering was $110,000,000 based on an initial share price of $16.00. During Contineum Therapeutics’ quiet period, underwriters and any insiders involved in the IPO are restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Analyst Ratings Changes

Several analysts recently commented on CTNM shares. Morgan Stanley began coverage on shares of Contineum Therapeutics in a research report on Tuesday, April 30th. They set an “overweight” rating and a $25.00 price target on the stock. Stifel Nicolaus began coverage on Contineum Therapeutics in a research report on Tuesday, April 30th. They set a “buy” rating and a $29.00 target price on the stock. Finally, Royal Bank of Canada assumed coverage on Contineum Therapeutics in a report on Tuesday, April 30th. They issued an “outperform” rating and a $30.00 price target for the company.

Contineum Therapeutics Stock Performance

Shares of NASDAQ CTNM opened at $14.81 on Wednesday. Contineum Therapeutics has a one year low of $13.27 and a one year high of $16.06.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).